Nutritional supplements and methods of nutritional supplementation affecting the endocannabinoid system are provided. These nutritional supplements and methods of nutritional supplementation support the endocannabinoid systems of subjects by providing a blend of hemp oil, black pepper oil, black cumin seed oil, and white frankincense oil to prime ECS receptors and activate them to provide improvements to the ECS in a subject, affecting their pain response, mood, stress response, and sleep.

Nutritional supplements and methods of nutritional supplementation affecting the endocannabinoid system are provided. These nutritional supplements and methods of nutritional supplementation support the endocannabinoid systems of subjects by providing a blend of hemp oil, black pepper oil, black cumin seed oil, and white frankincense oil to prime ECS receptors and activate them to provide improvements to the ECS in a subject, affecting their pain response, mood, stress response, and sleep.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

Kava and kratom compositions are described herein along with the methods of producing the same. The description contained herein describes methods for making a purified kava composition that is free or substantially free of flavokavain A and flavokavain B. In some embodiments, the kava composition is formulated as a ready-to-drink beverage. Certain compositions comprise a combination of a kava composition and a kratom composition made in accordance with the methods described herein.

Kava and kratom compositions are described herein along with the methods of producing the same. The description contained herein describes methods for making a purified kava composition that is free or substantially free of flavokavain A and flavokavain B. In some embodiments, the kava composition is formulated as a ready-to-drink beverage. Certain compositions comprise a combination of a kava composition and a kratom composition made in accordance with the methods described herein.

Kava and kratom compositions are described herein along with the methods of producing the same. The description contained herein describes methods for making a purified kava composition that is free or substantially free of flavokavain A and flavokavain B. In some embodiments, the kava composition is formulated as a ready-to-drink beverage. Certain compositions comprise a combination of a kava composition and a kratom composition made in accordance with the methods described herein.

The invention relates to a composition comprising at least one specific mixture of molecules for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel diseases in humans or animals.

The invention relates to a composition comprising at least one specific mixture of molecules for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel diseases in humans or animals.